ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by nVerses Capital LLC

nVerses Capital LLC decreased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 81.7% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,100 shares of the biotechnology company’s stock after selling 9,400 shares during the quarter. nVerses Capital LLC’s holdings in ADMA Biologics were worth $42,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Quest Partners LLC acquired a new stake in ADMA Biologics in the 2nd quarter worth about $29,000. EntryPoint Capital LLC purchased a new position in shares of ADMA Biologics during the 1st quarter worth about $31,000. USA Financial Formulas boosted its position in shares of ADMA Biologics by 8.6% in the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 539 shares during the last quarter. CWM LLC grew its holdings in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in ADMA Biologics in the second quarter valued at approximately $93,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Young Kwon sold 60,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $15.67 on Wednesday. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The company has a market cap of $3.63 billion, a PE ratio of -783.50 and a beta of 0.62. The company’s fifty day simple moving average is $18.04 and its 200-day simple moving average is $12.87. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $21.13.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm’s revenue was up 78.4% compared to the same quarter last year. During the same period last year, the company posted ($0.02) earnings per share. As a group, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ADMA. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a report on Monday, October 14th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.